Sarcomatrix

Sarcomatrix

Early Stage

Building Strength, Building Futures

Building Strength, Building Futures

Overview

Raised to Date: Raised: $29,505

Total Commitments ($USD)

Platform

StartEngine

Start Date

04/30/2024

Close Date

07/29/2024

Min. Goal
$15,000
Max. Goal
$1,235,000
Min. Investment

$500

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.50

Pre-Money Valuation

$14,250,000

Rolling Commitments ($USD)

Status

Active

Reporting Date

05/25/2024

Days Remaining

64

% of Min. Goal

197%

% of Max. Goal

2%

Likelihood of Max
unlikely
Avg. Daily Raise

$1,180

# of Investors

17

Momentum
cold.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2022

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

Reno, Nevada

Sarcomatrix, with a valuation of $14.25 million, is raising funds on StartEngine. The company is developing assets for the treatment of muscle diseases using innovative techniques. Sarcomatrix is in the pre-revenue and pre-commercialization stages of development, with two major assets nearing first-in-human clinical trials. The company aims to target the root causes of neuromuscular disorders rather than only addressing the symptoms and has received NIH grants for its research. David Craig founded Sarcomatrix in May 2022. The current crowdfunding campaign has a minimum target of $15,000 and a maximum target of $1.24 million. The campaign proceeds will be used for research and development, inventory, company employment, and working capital.

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-103,375

$0

Summary Balance Sheet

FY 2023 FY 2022

Cash

$36,803

$0

Accounts Receivable

$0

$0

Total Assets

$36,803

$0

Short-Term Debt

$18,894

$0

Long-Term Debt

$113,330

$0

Total Liabilities

$132,224

$0

Financials as of: 04/30/2024
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Sarcomatrix on StartEngine 2024
Platform: StartEngine
Security Type: Equity - Common
Valuation: $14,250,000
Price per Share: $2.50

Follow company

Follow Sarcomatrix on StartEngine 2024

Buy Sarcomatrix's Deal Report

Sarcomatrix Deal Report

Get KingsCrowd’s comprehensive report on Sarcomatrix including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sarcomatrix is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sarcomatrix deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge